
Confused over the conflicting COVID vaccine guidance? Here's what to know
Federal health officials have in recent weeks given conflicting — and at times confusing — guidance around who should get vaccinated against COVID-19. These changes mark a significant departure from the Centers for Disease Control and Prevention's previous recommendations, which advised everyone 6 months and older to get the vaccine.
On May 20, Dr. Marty Makary, commissioner of the Food and Drug Administration, published an article in the New England Journal of Medicine saying the FDA will make the vaccine available only to adults 65 and older and people with at least one underlying medical condition — meaning vaccines will no longer be recommended for healthy adults under 65.
On May 27, Health Secretary and longtime vaccine skeptic Robert F. Kennedy Jr. unilaterally announced that the federal government no longer recommends the vaccine for children and pregnant women, and that the vaccine was removed from the immunization schedule recommended by the Centers for Disease Control and Prevention.
But days later, the CDC partly contradicted this pronouncement, saying the vaccine will remain on the childhood immunization schedule — but added a new clarification that parents should consult with their children's doctor when deciding whether to get their child immunized. The CDC offered no formal guidance on whether pregnant women should get the vaccine, though its website lists pregnancy as an underlying condition that puts someone at higher risk of severe COVID and thus makes them eligible for vaccination going forward.
What should you do?
One practical thing to keep in mind, according to some experts, is you may just want to wait and see how things shake out. The next updated COVID vaccine, for 2025-26, won't be rolled out until the fall. And before then, we may get more clarity on who it will be recommended for — and thus whom health insurers will cover it for. Insurers typically pay for vaccines only if they're recommended by the federal government.
We may get clarification this month: The Advisory Committee on Immunization Practices, an outside panel of scientific experts that advises the CDC on vaccine recommendations, is scheduled to meet June 25-27 to vote on 2025-26 COVID vaccine recommendations.
Historically, this panel has advised the CDC director on vaccine recommendations, and the CDC then communicates its recommendations with the public. Kennedy bypassed this long-held protocol by going ahead and changing vaccine recommendations without input from the CDC's advisory panel.
As it stands:
Adults 65 and over
The recommendation for this group is not changing. Adults 65 and older should get the COVID vaccine every six months. This group can expect to get the same access to vaccination as they've had since the pandemic began, meaning their insurer should continue covering it since the federal government recommends it for them.
People 6 months and older with at least one underlying medical condition
The vaccinations are also still recommended for those in this age group with one or more underlying conditions putting them at higher risk for severe COVID.
Pregnant women
The federal government's position on whether pregnant women should get immunized is unclear. While Kennedy said the vaccine for pregnant women was no longer recommended by the CDC, the FDA's Makary said a day later that the decision to vaccinate should be made by the pregnant person and their doctor.
Infectious disease experts and obstetricians urge pregnant women to get the vaccine. This is because pregnant people who get COVID are more likely to develop severe disease, need hospitalization and ICU care, and experience pregnancy complications including preeclampsia, miscarriage, preterm birth and higher likelihood of developing blood clots, said Nadia Roan, a UCSF professor and senior investigator at Gladstone Institutes who studies immunology.
'There's a ton of data that's been generated over recent years suggesting that boosting or vaccination during pregnancy is beneficial,' said Roan, who is researching COVID boosters in pregnant people.
Also, getting immunized during pregnancy is the only way to pass protection on to the fetus, and have the infant protected in early life.
'If you vaccinate and you're in the third trimester, you're essentially vaccinating your fetus,' said Dr. George Rutherford, a professor emeritus of epidemiology and biostatistics at UCSF. 'That's a good thing because it's not approved for people under 6 months yet. So this is how we get to that population.'
If you're pregnant and wondering whether you should get the current 2024-25 vaccine now — in case you can't get the updated 2025-26 vaccine later due to new federal recommendations that have yet to be determined — 'I'd say yes because I'm not sure it'll be covered in the fall,' said Dr. Peter Chin-Hong, an infectious-disease specialist at UCSF.
'It's not harmful, particularly if you haven't had one in the last year,' he said.
The vaccine is safe to get at all stages of pregnancy, he said.
Healthy adults under 65
For this group, whether to get vaccinated is a little more open to interpretation, experts said, and can factor in things like each person's risk tolerance, job and living situation.
'I'd talk to their health care provider at the end of the day to help guide them more,' Chin-Hong said. 'Everyone has different situations and circumstances.'
You may want to lean toward vaccination if, for instance, you plan to travel this summer (when abroad, you don't have access to your usual health care providers) or if you live with immunocompromised or older adults and want to lower the chances of spreading COVID to them.
'In general, (healthy adults) are going to do fine, so to me it's really about protecting the people who are most vulnerable,' Chin-Hong said.
Children
About 2,000 children in the U.S. have died from COVID since 2020, and more than 200,000 have been hospitalized. Those numbers are much lower compared with people in higher-risk groups, especially those over 65, and most healthy children likely experience mild or moderate symptoms.
Still, many infectious diseases experts say the benefits of vaccination do still outweigh the risks — though that calculus is much closer than it is for pregnant people and adults over 65.
'It's a small number compared to deaths in many other age ranges, but that's deaths, many of which could've been prevented if they were vaccinated,' said Dr. John Swartzberg, a clinical professor emeritus of infectious diseases at UC Berkeley School of Public Health.
The vaccines have proved safe and effective in children, lower the likelihood of severe disease, and help reduce long COVID risk, Roan said.
'The risks (of vaccination) are very low, and these vaccines have been shown to be safe,' Roan said. 'So I think the benefits definitely outweigh the risks. But it's up to each individual to make that decision.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
This city is the worst for bed bugs in the US
You may not want to know this, but your city likely has bed bugs. In a new list, the pest control company Terminix has identified the 50 cities it treats the most for the pests. Bed bugs are blood-sucking insects that can quickly infest homes. It can take months to eradicate infestations. "We have seen a consistent increase in bed bug control service performed since the 'new normal' post-COVID-19 pandemic,' explained Terminix Technical Service Manager Eric Braun. To make the list, the company used service data from more than 300 branches across the country. The city of Montgomery, Alabama, came in at 50. 'When looking at which states appear the most, Ohio, Texas, Florida, California, and Pennsylvania dominate, suggesting regional trends in infestations are likely tied to climate, housing trends, and travel hubs,' Terminix said. Which cities are at the top of the list? Here are the 10 worst cities for bed bug infestations. Philadelphia takes the top spot for the second consecutive year. The City of Brotherly Love wasn't the only Pennsylvania hub on the list. Pittsburgh was ranked number 15. This may seem fairly self-explanatory. The Big Apple has consistently ranked high. But, New York is even higher on Terminix's list this year, climbing into the top five. So, has Cleveland. Terminix says its standing reflects continued struggles with these persistent pests. The City of Angels takes fourth. Big urban areas with a lot of food and warm temperatures are where bed bugs thrive. Dallas-Fort Worth rounds out the top five. The metropolitan area is frequently hit by summer storms. Atlanta may take the sixth slot, but this southern hub isn't even in Orkin's top 10 cities. Another Texas city! Last year, another list from Pest Gnome ranked the city, with a population of more than 2 million, in its third spot. The nation's capital has been in Orkin's number one spot before. On the West Coast, the San Francisco Bay Area also lands inside the top 10. That may be surprising if you're looking for the city on Orkin's recent list. It came in at 41 last year. Sacramento, Stockton, San Diego, and Modesto also rank within Terminix's top 50. Indiana's capital city might round out the top 10. But don't be fooled. There are plenty of other Midwest cities, such as Dayton, Columbus, Chicago, and Cincinnati. There are also cities in the South.

13 minutes ago
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease. Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older. Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults. More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when. Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk. The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC. Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine. As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations. meeting scheduled to be held between June 25 and June 27 Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine.
Yahoo
15 minutes ago
- Yahoo
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease. Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older. Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults. MORE: Despite 'game-changing' new RSV shots, uptake lagged among infants, adults: Experts More than one-third of adults between ages 18 and 59 have at least one underlying condition that puts them at increased risk of RSV, according to Moderna. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," Stéphane Bancel, CEO of Moderna, said in a press release. "We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV." Although the FDA approves vaccines and may expand approvals for certain age groups, the Centers for Disease Control and Prevention sets recommendations regarding who should get vaccines and when. Currently, the CDC recommends RSV vaccination only for those aged 75 and older and for those aged 60 and over at increased risk. The CDC's independent vaccine advisory committee will need to vote to recommend that the new age group be eligible for the shot, followed by a final recommendation from the director of the CDC. Earlier this week, Kennedy removed all 17 sitting members of the committee and replaced them with eight new members. It remains unclear how the new members of the panel will decide to approach recommendations for the RSV vaccine. MORE: Respiratory virus activity remains 'high' in US and will 'continue for several more weeks': CDC As of Friday, the CDC director role remains vacant and Health and Human Services Secretary Robert F. Kennedy Jr. has been making final recommendations. In an April meeting, the prior advisory committee voted to recommend RSV vaccination for those aged 50 to 59 with increased risk of disease, but Kennedy did not adopt the recommendations. Instead, it appears Kennedy plans to have the new committee re-discuss the recommendations for RSV vaccination as well as discuss HPV and COVID vaccinations in their meeting scheduled to be held between June 25 and June 27 Moderna's RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV vaccination has been lagging. As of April 26, the latest date for which CDC data is available, an estimated 47.5% of adults aged 75 and older and 38.1% of adults aged 60 to 74 with a high-risk condition reported ever having received an RSV vaccine. FDA expands approval of Moderna's RSV vaccine to some adults under age 60 originally appeared on